loading...| Preferred Name |
pazopanib hydrochloride |
|
| Synonyms |
GW786034B |
|
| Definitions |
The hydrochloride salt of a small molecule inhibitor of multiple protein tyrosine kinases with potential antineoplastic activity. Pazopanib selectively inhibits vascular endothelial growth factor receptors (VEGFR)-1, -2 and -3, c-kit and platelet derived growth factor receptor (PDGF-R), which may result in inhibition of angiogenesis in tumors in which these receptors are upregulated. Check for "https://www.cancer.gov/about-cancer/treatment/clinical-trials/intervention/C60779" active clinical trials using this agent. ("http://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI%20Thesaurus&code=C60779" NCI Thesaurus) |
|
| ID |
http://purl.bioontology.org/ontology/PDQ/CDR0000476479 |
|
| altLabel |
GW786034B 5-((4-((2,3-dimethyl-2h-indazol-6-Yl)methylamino)pyrimidin-2-yl)amino)-2-methylbenzenesulfonamide monohydrochloride Votrient |
|
| cui |
C1872226 C1882305 C2723822 |
|
| DATE FIRST PUBLISHED |
2006-04-07 |
|
| Date last modified |
2012-04-27 |
|
| definition |
The hydrochloride salt of a small molecule inhibitor of multiple protein tyrosine kinases with potential antineoplastic activity. Pazopanib selectively inhibits vascular endothelial growth factor receptors (VEGFR)-1, -2 and -3, c-kit and platelet derived growth factor receptor (PDGF-R), which may result in inhibition of angiogenesis in tumors in which these receptors are upregulated. Check for "https://www.cancer.gov/about-cancer/treatment/clinical-trials/intervention/C60779" active clinical trials using this agent. ("http://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI%20Thesaurus&code=C60779" NCI Thesaurus) |
|
| LT |
TRD |
|
| NCI ID |
C60779 |
|
| notation |
CDR0000476479 |
|
| ORIG STY |
Drug/agent |
|
| prefLabel |
pazopanib hydrochloride |
|
| tui |
T109 T121 |